PLXP PLx Pharma Inc.

18.73
+0.04  (+0%)
Previous Close 18.69
Open 18.26
52 Week Low 2.94
52 Week High 21.5
Market Cap $430,442,409
Shares 22,981,442
Float 22,467,176
Enterprise Value $407,696,764
Volume 513,708
Av. Daily Volume 612,847
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
VAZALORE 325 mg and 81 mg doses
Liquid-filled aspirin capsule
Approved
Approved
FDA approval announced March 1, 2021.
Locilex
Mild infections of diabetic foot ulcers
Phase 3
Phase 3
Phase 3 top-line data did not meet endpoints - October 25, 2016.

Latest News

  1. SPARTA, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 2,400 Rite Aid stores later in August.

    Rite Aid is also reserving shelf space with "Coming Soon" placeholders for all three SKUs -- VAZALORE 81 mg, 12 count; VAZALORE 81 mg…

    SPARTA, N.J., July 26, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 2,400 Rite Aid stores later in August.

    Rite Aid is also reserving shelf space with "Coming Soon" placeholders for all three SKUs -- VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count – to alert consumers about the new aspirin therapy that will soon be available.

    "Our commercial launch plans are well under way, and we are delighted that Rite Aid is preparing its stores for VAZALORE later this summer. We look forward to adding Rite Aid to the growing number of retail pharmacy leaders that are providing access to this innovative aspirin therapy," stated Natasha Giordano, Chief Executive Officer of PLx.

    About VAZALORE

    VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

    About PLx Pharma Inc. 

    PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

    To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

    Contact

    Investor Relations:

    Lisa M. Wilson, In-Site Communications, Inc.

    T: 212-452-2793

    E:

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/63eb4491-f9b7-4c20-9a6b-5cf48bc22c80



    Primary Logo

    View Full Article Hide Full Article
  2. SPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), announced today that the Company will release its 2021 second quarter financial results on Friday, August 6, 2021, before the U.S. financial markets open.

    Natasha Giordano, President and Chief Executive Officer, and Rita O'Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

    DateFriday, August 6, 2021

    SPARTA, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), announced today that the Company will release its 2021 second quarter financial results on Friday, August 6, 2021, before the U.S. financial markets open.

    Natasha Giordano, President and Chief Executive Officer, and Rita O'Connor, Chief Financial Officer, will host a conference call to discuss the results and provide a business update as follows:

    DateFriday, August 6, 2021
    Time8:30 a.m. ET
    Toll free (U.S.)(866) 394-2901
    International

    Conference ID
    (616) 548-5567

    8277376
    Webcast (live and replay)www.plxpharma.com under the ‘Investor Relations' section.

    A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The conference ID for the replay is 8277376. The archived webcast will be available for 30 days via the aforementioned URL.

    About VAZALORE

    VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

    About PLx Pharma Inc.

    PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

    To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

    Contact

    Investor Relations:

    Lisa M. Wilson, In-Site Communications, Inc.

    T: 212-452-2793

    E:



    Primary Logo

    View Full Article Hide Full Article
  3. SPARTA, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.

    Walgreens has already inserted placeholders to reserve space on shelves for all…

    SPARTA, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 8,000 Walgreens stores nationwide later in August. Walgreens is a global leader in retail pharmacy.

    Walgreens has already inserted placeholders to reserve space on shelves for all three SKUs: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count.

    "As we continue to execute on our commercial launch plans, we are delighted that Walgreens has committed to carrying all three SKUs of VAZALORE in over 8,000 of its stores throughout the country. Walgreens' focus on health and wellbeing aligns closely with our mission to bring VAZALORE to the millions of people who can benefit from our unique aspirin therapy," stated Natasha Giordano, Chief Executive Officer of PLx.

    About VAZALORE

    VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

    About PLx Pharma Inc. 

    PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

    To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

    Contact

    Investor Relations:

    Lisa M. Wilson, In-Site Communications, Inc.

    T: 212-452-2793

    E:

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0a91fca5-c90b-4bb9-b5e1-f4189df5f818

     



    Primary Logo

    View Full Article Hide Full Article
  4. SPARTA, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August.

    The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. Walmart, one…

    SPARTA, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), today announced that three stock-keeping units ("SKUs") of VAZALORE, the first and only U.S. Food and Drug Administration ("FDA") approved liquid-filled aspirin capsules, will be available in over 4,500 Walmart stores across the United States in mid-August.

    The three SKUs include: VAZALORE 81 mg, 12 count; VAZALORE 81 mg, 30 count; and VAZALORE 325 mg, 30 count. Walmart, one of the largest retailers in the world, has already inserted placeholders to reserve space on shelves and alert customers that VAZALORE is coming soon.

    "We are so excited that Walmart has committed to "Coming Soon" shelf placeholders for the next few weeks in anticipation of the stocking of all three SKUs of VAZALORE. With Walmart's broad reach and millions of customers, patients will have easy access to VAZALORE in most of their stores nationwide," stated Natasha Giordano, Chief Executive Officer of PLx. "Walmart's commitment is a real tribute to their recognition of VAZALORE as an innovative aspirin therapy."

    About VAZALORE

    VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting. To learn more about VAZALORE, please visit www.vazalore.com.

    About PLx Pharma Inc. 

    PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

    To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

    Contact

    Investor Relations:

    Lisa M. Wilson, In-Site Communications, Inc.

    T: 212-452-2793

    E:

    A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/9f2f01e3-74c4-43e8-8b79-9b13d783bd7e 



    Primary Logo

    View Full Article Hide Full Article
  5. SPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O'Connor, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows:

    The JMP Securities Life Sciences Conference:
      
    Date:Wednesday, June 16, 2021
      
    Time:12:30PM Eastern Time
      
    Webcast Link:https://wsw.com/webcast/jmp49/plxp/1710800
      
    The Raymond James Human

    SPARTA, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ:PLXP) ("PLx" or the "Company"), a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as "VAZALORE"), announced today that Natasha Giordano, President and Chief Executive Officer, and Rita O'Connor, Chief Financial Officer, will present virtually at two upcoming healthcare conferences as follows:

    The JMP Securities Life Sciences Conference:

      
    Date:Wednesday, June 16, 2021
      
    Time:12:30PM Eastern Time
      
    Webcast Link:https://wsw.com/webcast/jmp49/plxp/1710800
      
    The Raymond James Human Health Innovation Conference 2021:
      
    Date:Monday, June 21, 2021
      
    Time:2:40PM Eastern Time
      
    Webcast Link:https://kvgo.com/rj-health/plx-pharma-inc-june-2021

    The presentations will be webcast live at the aforementioned times, and archived for 30 days thereafter, via the Company's website at www.plxpharma.com, under the ‘Investors Relations' Section.

    About VAZALORE

    VAZALORE is an FDA-approved liquid-filled aspirin capsule that provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable and predictable platelet inhibition as compared to enteric-coated aspirin. It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.

    About PLx Pharma Inc. 

    PLx Pharma Inc. is a specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard™ drug delivery platform to provide more effective and safer products. The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach erosions and ulcers associated with certain drugs.

    To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

    Contact

    Investor Relations:

    Lisa M. Wilson, In-Site Communications, Inc.

    T: 212-452-2793

    E:



    Primary Logo

    View Full Article Hide Full Article
View All PLx Pharma Inc. News